To hear about similar clinical trials, please enter your email below
Trial Title:
Prognostic Models for HCC Based on Tumor Micronecrosis
NCT ID:
NCT05837065
Condition:
Hepatocellular Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Conditions: Keywords:
Hepatocellular Carcinoma
Tumor micronecrosis
Nomogram
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
observing whether HCC patients having tumor micronecrosis
Description:
whether HCC patients having tumor micronecrosis or not
Arm group label:
training cohort
Arm group label:
validation cohort
Summary:
The heterogeneity of hepatocellular carcinoma (HCC) leads to the unsatisfying predicting
performance of current staging systems. HCC patients with pathological tumor
micronecrosis have immunosuppressive microenvironment. We aimed to develop novel
prognostic models by integrating micronecrosis to more precisely predict the survival of
HCC patients after hepatectomy.
Criteria for eligibility:
Study pop:
This retrospective study enrolled HCC patients receiving curative hepatectomy in the
First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) (n = 765)
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. pathologically diagnosed as HCC;
2. curative hepatectomy with R0 resection;
3. conserved liver function with Child Pugh class A or B
Exclusion Criteria:
1. with macrovascular invasion or extrahepatic metastasis;
2. receiving other anti-tumor treatments such as TACE or systemic drugs;
3. with other primary cancers;
4. incomplete follow-up data;
5. without sufficient formalin-fixed, paraffin-embedded (FFPE) specimens for
micronecrosis evaluation
Gender:
All
Minimum age:
18 Years
Maximum age:
90 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
the First Affiliated Hospital, School of Medicine, Zhejiang University
Address:
City:
Hangzhou
Zip:
310003
Country:
China
Status:
Recruiting
Contact:
Last name:
Tingbo Liang, MD, PHD
Phone:
086-571-87236688
Email:
liangtingbo@zju.edu.cn
Start date:
September 15, 2022
Completion date:
December 30, 2023
Lead sponsor:
Agency:
Zhejiang University
Agency class:
Other
Source:
Zhejiang University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05837065
